Fei Xie

Fei Xie

Auto-generated profile, based on publicly available information

Fei Xie

National Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing, China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 June 2025 in Nature Chemical Biology
Verified
Journal Article
Closed access
PDF file
DXDian Xiao
Dian Xiao
JDJingwen Dong
Jingwen Dong
FXFei Xie
Fei Xie
XFXun Feng
Xun Feng
JWJianfeng Wang
Jianfeng Wang
SLSong Li
Song Li

1 September 2020 in Cancer Medicine
Verified
Journal Article
Open access
CCChunyan Cui
Chunyan Cui
HLHaojiang Li
Haojiang Li
HMHuali Ma
Huali Ma
ADAnnan Dong
Annan Dong
FXFei Xie
Fei Xie
LLLizhi Liu
Lizhi Liu
Objectives: We aimed to reconstitute T2 and T3 stage classification in nasopharyngeal carcinoma (NPC) cases and verify its utility in clinical settings.Materials and Methods: We enrolled 792 NPC patients. Cox proportional hazards model was used to compare the effect sizes (hazard ratio [HR]) of the cranial structure invasion on survival and select the structures for up‐staging or downstaging T2 and T3 NPC. The samples were reclassified and the survival curves for T2 and T3 stages were analyzed. The proposed new staging system was validated on an external sample (n = 433).Results: Thirteen cranial structures were examined. American Joint Committee on Cancer (AJCC) T3 stage patients with the invasion of the base of the sphenoid (HR = 2.58, 95% CI = 1.16‐5.77) or base of the pterygoid (HR = 2.00, 95% CI = 0.84‐4.77) had significantly lower hazard ratios than T2 stage patients with the invasion of soft tissues in the bilateral parapharyngeal space (HR = 5.26, 95% CI = 2.02‐13.68) and single/bilateral carotid sheath (HR = 7.78, 95% CI = 3.06‐19.76). T3 stage with the invasion of the above‐mentioned bones was reclassified as T2, and T2 stage with the invasion of the above‐mentioned soft‐tissue structures was reclassified as T3. Survival analysis showed a significant difference between the reclassified T2 and T3 stages (P < 0.001). The results were replicated in the validation samples.Conclusion: The proposed staging system for defining T2 and T3 stage NPC appears to be superior to the AJCC 8th edition. It could improve prognosis and optimize the treatment selection.

9 August 2022 in BMC Surgery
Verified
Journal Article
Open access
PDF file
WPWei Peng
Wei Peng
JSJunyi Shen
Junyi Shen
JDJunlong Dai
Junlong Dai
SLShusheng Leng
Shusheng Leng
FXFei Xie
Fei Xie
TWTianfu Wen
Tianfu Wen
Aims: This study aimed to evaluate the clinical significance of the preoperative aminotransferase to albumin ratio (AAR) in patients with hepatocellular carcinoma (HCC) after hepatectomy. Methods: From five hospitals, a total of 991 patients with HCC admitted between December 2014 and December 2019 were included as the primary cohort and 883 patients with HCC admitted between December 2010 and December 2014 were included as the validation cohort. The X-tile software was conducted to identify the optimal cut-off value of AAR. Results: In the primary cohort, the optimal cut-off value of the AAR was defined as 0.7 and 1.6, respectively. Compared to patients with AAR 0.7–1.6, those with AAR > 1.6 showed significantly worse overall survival (OS) and RFS, whereas those with AAR < 0.7 showed significantly better OS and RFS (all p < 0.001). Pathologically, patients with AAR > 1.6 had more aggressive tumour characteristics, such as larger tumour size, higher incidence of microvascular invasion, and severe histologic activity, and higher AFP level than patients with AAR < 0.7. Consistently, the abovementioned clinical significance of AAR was confirmed in the validation cohort. Conclusions: A high AAR was significantly correlated with advanced tumours and severe hepatic inflammation, and a worse prognosis of HCC.

26 June 2025 in Nature Chemical Biology
Verified
Journal Article
Open access
PDF file
DXDian Xiao
Dian Xiao
JDJingwen Dong
Jingwen Dong
FXFei Xie
Fei Xie
XFXun Feng
Xun Feng
JWJianfeng Wang
Jianfeng Wang
SLSong Li
Song Li
, the text "enhanced green fluorescent protein-targeting" was incorrect; it has now been amended to "epidermal growth factor receptor-targeting". In Figs. 3a, b, d, e and 4b and d, "K d " has been amended to "KD".

4 October 2026 in Nature Communications
Verified
Journal Article
Open access
PDF file
XFXun Feng
Xun Feng
LYLunzhi Yuan
Lunzhi Yuan
LZLei Zhao
Lei Zhao
LLLianqi Liu
Lianqi Liu
FXFei Xie
Fei Xie
SLSong Li
Song Li
Long-acting drug–Fc conjugate (CD388) has emerged as a new class of antivirals against influenza A and B, yet the mechanisms governing how Fc conjugation reshapes small-molecule function remain undefined. Here we establish a programmable multivalent antiviral conjugates (AVCs) platform by click chemistry that enables flexible combination of valencies and conjugated drugs, allowing systematic interrogation of valency-dependent antiviral mechanisms. Using zanamivir as a model, mono-, di-, and trivalent zanamivir are conjugated with Fc, with trivalent zanamivir-Fc conjugates (AVC-Z3) exhibiting higher activity than lower-valent AVCs. AVC-Z3 induces inter-virion aggregation, thereby coupling blockade of viral entry with restriction of viral release. This cross-linking–mediated dual-stage inhibition represents a mechanistic shift from neuraminidase suppression to physical viral immobilization. Furthermore, trivalent peramivir-Fc conjugate (AVC-P3) is synthesised and exhibits stronger antiviral activity than AVC-Z3 in vitro, with much longer half-life in vivo than AVC-Z3, and CD388 with YTE mutation. The in vivo antivirus efficacy of AVC-P3 surpasses other AVCs, baloxavir, and CD388 in H1N1-, H3N2-, H5N1-, and influenza B-infection mice models. Together, our findings define ligand valency as a determinant of antiviral mechanism.